Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Share-based Compensation (2016 - 2025)

Palisade Bio has reported Share-based Compensation over the past 16 years, most recently at $3.7 million for Q4 2025.

  • Quarterly Share-based Compensation rose 945.91% to $3.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, up 2463.86% year-over-year, with the annual reading at $3.9 million for FY2025, 2806.67% up from the prior year.
  • Share-based Compensation was $3.7 million for Q4 2025 at Palisade Bio, up from $85000.0 in the prior quarter.
  • Over five years, Share-based Compensation peaked at $3.7 million in Q4 2025 and troughed at -$440000.0 in Q4 2024.
  • The 5-year median for Share-based Compensation is $125000.0 (2024), against an average of $368000.0.
  • Year-over-year, Share-based Compensation crashed 172.61% in 2024 and then soared 945.91% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $103000.0 in 2021, then dropped by 16.5% to $86000.0 in 2022, then skyrocketed by 604.65% to $606000.0 in 2023, then crashed by 172.61% to -$440000.0 in 2024, then soared by 945.91% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Share-based Compensation are $3.7 million (Q4 2025), $85000.0 (Q3 2025), and $60000.0 (Q2 2025).